2202
Asthma Therapy I: Biologics
Saturday, March 5, 2016: 9:45 AM-10:45 AM
Convention Center, Level One, South Exhibit Hall H
Poster Session
0.00 CME/CE
35
Retrospective Observational Study to Evaluate Long-Term Effectiveness and Safety of Omalizumab Treatment in Real-Life Setting in Allergy Centre of Spain
Dorkas Margarita Marquez Hernandez Jose A Bastidas Lys Herraez Elena Mederos A. Enriquez Matas, MD Ruth Mielgo Ballesteros, MD Consuelo Fernandez
36
Efficacious Use of Omalizumab in the Treatment of Cystic Fibrosis
Diana Pham Hoang Pham, MD 2016, BSc, BA Ena Gaudet, RN Shawn Aaron, MD Stephanie Santucci, RN William H. Yang, MD
38
Impact of Visit Compliance on Response to Omalizumab Therapy in a Real-Life Clinical Setting: Reality Study
Harjinder Singh, MD Jay Peters, MD Yogeet Kaur, MS Joseph D. Diaz, MD
39
Omalizumab Can be Effective in Patients with Allergic Bronchopulmonary Aspergillosis
John W. O'Quinn, MD Diana Pham Hoang Pham, MD 2016, BSc, BA Gonzalo G. Alvarez, MD Istvan T. Bencze, MD Krishna B. Sharma, MD Mark Smith, MD Shawn Aaron, MD Jennifer Block, MD Tara Keays, MD Judith Leech, MD David Schneidermen, MD Jodi Cameron, RPN Jennifer Forgie, RN Alicia Ring, RPN Stephanie Santucci, RN William H. Yang, MD
40
Rapid Lung Function Improvement with Lebrikizumab in Patients with Uncontrolled Asthma
Jonathan  Corren, MD Nicola A. Hanania, MD Phillip E. Korenblat, MD, FAAAAI Julie K. Olssen, MD, MS Nikhil Kamath, MD Sarah Gray, PhD Nicolas Martin Cecile T.J. Holweg, PhD John G. Matthews, MB, BS, MRSCP, PhD Susan L. Limb, MD Stephan Korom
41
Biomarkers Associated with Response in Patients Initiating Omalizumab: Baseline Levels Among Patients in the Prospective Observational Study to Evaluate Predictors of Clinical Effectiveness in Response to Omalizumab (PROSPERO) Study
Bradley E. Chipps, MD FAAAAI William W. Busse, MD FAAAAI Allan T. Luskin, MD Robert S. Zeiger, MD PhD FAAAAI Benjamin Trzaskoma, MS Hooman Pazwash Theodore A. Omachi, MD, MBA Thomas B. Casale, MD FAAAAI
42
Poor Asthma Control Is Associated with Overall Daily Activity Impairment: 3-Year Data from the EXCELS Study of Omalizumab
Evgeniya Antonova, MS, PhD Benjamin Trzaskoma, MS Theodore A. Omachi, MD, MBA Michael Schatz, MD MS FAAAAI
43
Long-Term Safety and Efficacy of Mepolizumab in Patients with Severe Eosinophilic Asthma
Frank C. Albers, M.D., Ph.D. Njira Lugogo Martyn J Gilson Robert Price Steven W Yancey
45
Interleukin-15 Overexpression Protect Mice from the Allergen-Induced Airway Obstruction
Sathisha Upparahalli Venkateshaiah, PhD Murli Manohar Chandrashekara Puthanapura Mahadevappa, PhD Anil Mishra, PhD FAAAAI
46
The Extent of Serum Periostin Reduction in Asthma Patients Treated with Lebrikizumab Is Related to Baseline Periostin Levels: A Pooled Analysis of Phase II Studies
David F Choy Cecile T.J. Holweg, PhD Fang Cai Joseph R. Arron John G. Matthews, MB, BS, MRSCP, PhD Heleen Scheerens, PhD
47
Response to Omalizumab Therapy Based on Level of IgE: A Two Year Observational Study (REALITY Study)
Jay Peters, MD Harjinder Singh, MD Yogeet Kaur, MS Joseph D. Diaz, MD
48
Blood Eosinophils and Serum IgE Predict Response to Omalizumab in Patients with Severe Allergic Asthma: Innovate Trial Post-Hoc Analysis
Volkan Manga, MD Marc Humbert, MD PhD Ratko Djukanovic Steve Greenberg, MD Theodore A. Omachi, MD, MBA Benjamin Trzaskoma, MS Roland Buhl
49
Steroid Sparing Response with Mepolizumab: Durability of Steroid Reduction in Severe Asthma
Charlene M. Prazma, PhD Elisabeth H. Bel, MD PhD Neil C Barnes, MD Robert Price Frank C Albers Steven W Yancey
50
Omalizumab and Severe Alergic Asthma : Assessment after 1 Year of Treatment
Rita Aguiar, MD Ana M. Mendes, MD Ana Célia Costa, MSc Fatima Duarte, MD Estrella Alonso Anabela Lopes, MD Elisa Pedro, MD Manuel Pereira-Barbosa
See more of: Abstracts